News Daily News STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF Shelley Wood October 17, 2022
News Industry News Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan) July 07, 2015